Factory 99% Ponatinib Powder CAS 943319-70-8 Chemical Intermediate Anti-Cancer Ponatinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A554
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Ponatinib
• CAS: 943319-70-8
• Appearance: Yellow Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Anti-Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Ponatinib
Appearance	Yellow Powder
CAS NO.	943319-70-8
MF	C29H27F3N6O
Storage	Keep in a cool, dry, dark location

 

Ponatinib, also known as AP24534, is a potent oral multi-target kinase inhibitor. It belongs to the class of drugs known as tyrosine kinase inhibitors (TKIs). The molecular formula of Ponatinib is C29H27F3N6O, and it has a molecular weight of 532.56.

 

1. Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Ponatinib is primarily used to treat adults with CML and Ph+ ALL, particularly those who are resistant or intolerant to other tyrosine kinase inhibitors.

2. Advanced Solid Tumors: In addition to its use in hematological malignancies, Ponatinib has also shown promise in the treatment of certain advanced solid tumors, such as gastrointestinal stromal tumors (GIST) and hepatocellular carcinoma, although its use in these indications is less common and typically investigational.

3. Recurrent or Refractory Lymphomas: Ponatinib has been explored as a treatment option for certain recurrent or refractory lymphomas, including non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL), although its primary indications remain in the treatment of leukemias.

1. Inhibition of Kinase Activity: Ponatinib functions by inhibiting the activity of specific kinases, including BCR-ABL, which is a key driver of CML and certain other leukemias.

2. Selective Targeting: Ponatinib exhibits selectivity for its targets, allowing it to disrupt the growth and proliferation of malignant cells while minimizing impact on normal cells.

3. Overcoming Drug Resistance: Ponatinib is particularly notable for its ability to inhibit the T315I mutant form of BCR-ABL, which is a common cause of resistance to other tyrosine kinase inhibitors.